Clinico-pathologic and dynamic prognostic factors in sporadic and familial medullary thyroid carcinoma: an Israeli multi-center study.

Objective Multiple clinical, pathological and biochemical variables, including the response to initial treatment, are associated with medullary thyroid carcinoma (MTC) prognosis. Studies that include separate analyses of familial and sporadic MTC patients followed for long period are scarce. This study evaluated the association between baseline clinico-pathologic variables and response to initial treatment and short- and long-term disease outcomes in sporadic and familial MTC. Methods Patients treated for MTC at four tertiary medical centers were retrospectively analyzed. Clinical and pathological data were collected. The outcomes measured included disease persistence 1 year after diagnosis, disease persistence at last follow-up, disease-related mortality (DRM) and all-cause mortality. Results The study enrolled 193 patients (mean age: 48.9 ± 18.7, 44.7% males), of whom 18.1% were familial cases. The mean follow-up period was 10.1 ± 9.4 years (8.5 ± 8.1 in sporadic and 16.9 ± 11.6 in familial MTC). Disease persistence 1-year after diagnosis and at last follow-up was detected in 56.1 and 60.4% patients, respectively. All-cause and DRM were 28.5 and 12.6%, respectively. Extra-thyroidal extension (ETE) and distant metastases (DM) were associated with disease persistence at last follow-up. ETE and DM were also significantly associated with DRM. Complete remission 1 year after diagnosis had high correlation with no evidence of disease at last follow-up (Cramer's V measure of association 0.884, P < 0.001) and with 100% disease-specific survival (Cramer's V measure of association 0.38, P < 0.001). Conclusions Apart from clinico-pathologic parameters, close correlation was found between 1-year status and long-term prognosis. These results underscore the importance of combining classical and dynamic factors for both sporadic and familial MTC prognostication and treatment decision making.

[1]  Wei Ge,et al.  Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker. , 2018, The oncologist.

[2]  C. Benbassat,et al.  Temporal Trends in the Presentation, Treatment, and Outcome of Medullary Thyroid Carcinoma: An Israeli Multicenter Study. , 2018, Thyroid : official journal of the American Thyroid Association.

[3]  S. Sidhu,et al.  Medullary Thyroid Carcinoma: Survival Analysis and Evaluation of Mutation-Specific Immunohistochemistry in Detection of Sporadic Disease , 2018, World Journal of Surgery.

[4]  Tae Hyung Kim,et al.  Dynamic risk stratification in medullary thyroid carcinoma , 2018, Medicine.

[5]  S. Roman,et al.  Rethinking the Current American Joint Committee on Cancer TNM Staging System for Medullary Thyroid Cancer , 2017, JAMA surgery.

[6]  B. Burkey,et al.  PROGNOSTIC VARIABLES AFFECTING PRIMARY TREATMENT OUTCOME FOR MEDULLARY THYROID CANCER. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[7]  BarchanaMicha,et al.  Trends of Second Primary Malignancy in Patients with Thyroid Cancer: A Population-Based Cohort Study in Israel , 2017 .

[8]  N. Qu,et al.  Prognostic significance and optimal cutoff of age in medullary thyroid cancer , 2016, Oncotarget.

[9]  Jeong Hyun Lee,et al.  Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy , 2016, Endocrine.

[10]  R. Tuttle,et al.  Integration of a postoperative calcitonin measurement into an anatomical staging system improves initial risk stratification in medullary thyroid cancer , 2015, Clinical endocrinology.

[11]  M. Kattan,et al.  Postoperative Nomogram for Predicting Cancer-Specific Mortality in Medullary Thyroid Cancer , 2015, Annals of Surgical Oncology.

[12]  I. Ganly,et al.  Response to initial therapy predicts clinical outcomes in medullary thyroid cancer. , 2015, Thyroid : official journal of the American Thyroid Association.

[13]  I. Ganly,et al.  Risk stratification in medullary thyroid cancer: moving beyond static anatomic staging. , 2013, Oral oncology.

[14]  H. Dralle,et al.  Prognostic Impact of N Staging in 715 Medullary Thyroid Cancer Patients: Proposal for a Revised Staging System , 2013, Annals of surgery.

[15]  G. Agarwal,et al.  Medullary Thyroid Cancer: Clinico-pathological Profile and Outcome in a Tertiary Care Center in North India , 2011, World Journal of Surgery.

[16]  J. Moley,et al.  Medullary, anaplastic, and metastatic cancers of the thyroid. , 2010, Seminars in oncology.

[17]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[18]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[19]  S. Mandel,et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[20]  C. Pirich,et al.  Long‐term prognosis of medullary thyroid carcinoma , 2008, Clinical endocrinology.

[21]  C. Eisenberger,et al.  Long-Term Clinical and Biochemical Follow-up in Medullary Thyroid Carcinoma: A Single Institution's Experience Over 20 Years , 2007, Annals of surgery.

[22]  C. Benbassat,et al.  Medullary thyroid cancer: a retrospective analysis of a cohort treated at a single tertiary care center between 1970 and 2005. , 2007, Thyroid : official journal of the American Thyroid Association.

[23]  A. Toniato,et al.  Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[24]  S. Roman,et al.  Prognosis of medullary thyroid carcinoma , 2006, Cancer.

[25]  Q. Duh,et al.  Medullary thyroid carcinoma , 2000, Cancer.

[26]  M. Schlumberger,et al.  Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients , 1998 .

[27]  R. Tsang,et al.  Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. , 1996, Thyroid : official journal of the American Thyroid Association.

[28]  L. Keinan-Boker,et al.  Trends of Second Primary Malignancy in Patients with Thyroid Cancer: A Population-Based Cohort Study in Israel. , 2017, Thyroid : official journal of the American Thyroid Association.

[29]  Kaliszewski,et al.  American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer : The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer , 2017 .

[30]  A. Chou,et al.  Medullary Thyroid Carcinoma: Long-Term Outcomes of Surgical Treatment , 2010, Annals of Surgical Oncology.

[31]  M. Schlumberger,et al.  Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. , 1998, Clinical endocrinology.

[32]  R. Bergström,et al.  Long term follow‐up of patients with medullary carcinoma of the thyroid , 1997, Cancer.

[33]  C. Amos,et al.  Hereditary medullary thyroid carcinoma: genetic annalysis of three related syndromes. Groupe d'Etude des Tumeurs a Calcitonine. , 1989, Henry Ford Hospital medical journal.